(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.86%) $83.13
(-1.16%) $1.619
(-0.42%) $2 337.30
(-0.13%) $27.50
(0.63%) $927.90
(-0.17%) $0.933
(-0.12%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
5.10% INR 1 664.80
Live Chart Being Loaded With Signals
Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I...
Stats | |
---|---|
Šios dienos apimtis | 89 538.00 |
Vidutinė apimtis | 88 459.00 |
Rinkos kapitalizacija | 159.77B |
EPS | INR0 ( 2024-02-02 ) |
Kita pelno data | ( INR0 ) 2024-05-06 |
Last Dividend | INR3.00 ( 2023-09-21 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 64.10 |
ATR14 | INR2.17 (0.13%) |
Tūris Koreliacija
Poly Medicure Limited Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Poly Medicure Limited Koreliacija - Valiuta/Žaliavos
Poly Medicure Limited Finansinės ataskaitos
Annual | 2022 |
Pajamos: | INR11.15B |
Bruto pelnas: | INR7.09B (63.61 %) |
EPS: | INR18.69 |
FY | 2022 |
Pajamos: | INR11.15B |
Bruto pelnas: | INR7.09B (63.61 %) |
EPS: | INR18.69 |
FY | 2022 |
Pajamos: | INR9.17B |
Bruto pelnas: | INR4.84B (52.75 %) |
EPS: | INR15.28 |
FY | 2021 |
Pajamos: | INR7.75B |
Bruto pelnas: | INR4.39B (56.59 %) |
EPS: | INR15.25 |
Financial Reports:
No articles found.
Poly Medicure Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR3.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.375 | 2012-09-13 |
Last Dividend | INR3.00 | 2023-09-21 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | INR20.13 | -- |
Avg. Dividend % Per Year | 0.27% | -- |
Score | 2.15 | -- |
Div. Sustainability Score | 4.15 | |
Div.Growth Potential Score | 5.12 | |
Div. Directional Score | 4.63 | -- |
Year | Amount | Yield |
---|---|---|
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.00 | 0.80% |
2019 | INR2.00 | 0.90% |
2020 | INR2.00 | 0.92% |
2021 | INR2.50 | 0.49% |
2022 | INR2.50 | 0.26% |
2023 | INR3.00 | 0.33% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SARDAEN.NS | Dividend Junior | 2023-09-07 | Annually | 15 | 0.65% | |
MAGADSUGAR.NS | Dividend Junior | 2023-07-13 | Annually | 7 | 1.78% | |
GMDCLTD.NS | Dividend Knight | 2023-09-22 | Annually | 23 | 3.41% | |
ASTRAMICRO.NS | Dividend Junior | 2023-08-23 | Annually | 20 | 0.49% | |
TITAN.NS | Dividend Junior | 2023-07-13 | Annually | 20 | 0.35% | |
PETRONET.NS | Dividend Knight | 2023-08-18 | Semi-Annually | 18 | 2.36% | |
JASH.NS | Dividend Junior | 2023-09-22 | Annually | 7 | 0.57% | |
DBOL.NS | Dividend Junior | 2023-06-23 | Insufficient data to determine frequency | 2 | 0.56% | |
SILINV.NS | Dividend Junior | 2023-08-18 | Annually | 23 | 0.63% | |
MBAPL.NS | Dividend Junior | 2023-09-18 | Annually | 8 | 0.44% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.191 | 1.500 | 6.19 | 9.28 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.193 | 1.500 | 8.97 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 30.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.15 | 2.00 | 6.62 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.15 | 2.00 | 4.93 | 9.85 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.650 | 1.000 | 2.50 | 2.50 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.248 | 1.000 | 7.04 | 7.04 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.15 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 63.00 | 1.000 | 3.74 | 0 | [1 - 100] |
returnOnEquityTTM | 0.193 | 2.50 | 9.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.15 | 2.00 | 6.62 | 9.85 | [0 - 30] |
dividendYielPercentageTTM | 0.184 | 1.500 | 5.41 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.15 | 2.00 | 6.62 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 320.27 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0746 | 1.000 | -0.634 | 0 | [0.1 - 0.5] |
Total Score | 5.12 |
Poly Medicure Limited
Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. In addition, it offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. Further, it provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. The company was incorporated in 1995 and is based in New Delhi, India.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.